Inhibition of glycogen synthase kinase-3β suppresses inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes and collagen-induced arthritis

Joint Bone Spine

Volumn 81, Issue 3, 2014, Pages 240-246

  Kwon, Yong Jin ^a   Yoon, Chong Hyeon ^b   Lee, Sang Won ^a   Park, Yong Beom ^a   Lee, Soo Kon ^a   Park, Min Chan ^a  

^a Yonsei University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Collagen induced arthritis; Fibroblast like synoviocytes; Glycogen synthase kinase 3 ; Rheumatoid arthritis

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; 6 BROMOINDIRUBIN 3' OXIME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACTIVATING TRANSCRIPTION FACTOR 2; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LITHIUM CHLORIDE; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; INTERLEUKIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; FIBROBLAST; GENE EXPRESSION; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; T LYMPHOCYTE; ARTHRITIS; DRUG SELECTIVITY; ENZYME INHIBITION; HISTOLOGY; MACROPHAGE; PROTEIN EXPRESSION;

COLLAGEN-INDUCED ARTHRITIS; FIBROBLAST-LIKE SYNOVIOCYTES; GLYCOGEN SYNTHASE KINASE-3Β; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROBLASTS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INFLAMMATION; MICE; SYNOVIAL MEMBRANE;

EID: 84901360422     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.09.006     Document Type: Article

References (40)

1. Handel M.L., McMorrow L.B., Gravallese E.M. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995, 38:1762-1770.
2. Gerlag D.M., Ransone L., Tak P.P., et al. The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol 2000, 165:1652-1658.
3. Marok R., Winyard P.G., Coumbe A., et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996, 39:583-591.
4. Thalhamer T., McGrath M.A., Harnett M.M. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47:409-414.
5. Han Z., Boyle D.L., Chang L., et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001, 108:73-81.
6. David J.P., Sabapathy K., Hoffmann O., et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and independent mechanisms. J Cell Sci 2002, 115:4317-4325.
7. Suzuki M., Tetsuka T., Yoshida S., et al. The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts. FEBS Lett 2000, 465:23-27.
8. Westra J., Limburg P.C., de Boer P., et al. Effects of RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 2004, 63:1453-1459.
9. Matsumoto M., Sudo T., Saito T., et al. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000, 275:31155-31161.
10. Frame S., Cohen P. GSK-3 takes centre stage more than 20 years after its discovery. Biochem J 2001, 359:1-16.
11. Van Wauwe J., Haefner B. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention. Drug News Perspect 2003, 16:557-565.
12. Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev 2008, 28:773-796.
13. Forde J.E., Dale T.C. Glycogen synthase kinase-3: a key regulator of cellular fate. Cell Mol Life Sci 2007, 64:1930-1944.
14. Kockeritz L., Doble B., Patel S., et al. Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr Drug Targets 2006, 7:1377-1388.
15. Wada A. GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front Biosci 2009, 14:1558-1570.
16. Martin M., Rehani K., Jope R.S., et al. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase-3. Nat Immunol 2005, 6:777-784.
17. Dugo L., Collin M., Allen D.A., et al. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 2005, 33:1903-1912.
18. Whittle B.J., Varga C., Posa A., et al. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol 2006, 147:575-582.
19. Cuzzocrea S., Crisafulli C., Mazzon E., et al. Inhibition of glycogen synthase kinase-3beta attenuates the development of carrageenan-induced lung injury in mice. Br J Pharmacol 2006, 149:687-702.
20. Bao Z., Lim S., Liao W., et al. Glycogen synthase kinase-3beta inhibition attenuates asthma in mice. Am J Respir Crit Care Med 2007, 176:431-438.
21. Cuzzocrea S., Di Paola R., Mazzon E., et al. Glycogen synthase kinase-3beta inhibition reduces the development of non-septic shock induced by zymosan in mice. Shock 2007, 27:97-107.
22. Hoeflich K.P., Luo J., Rubie E.A., et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406:86-90.
23. De Ketelaere A., Vermeulen L., Vialard J., et al. Involvement of GSK-3β in TWEAK-mediated NF-kB activation. FEBS Lett 2004, 566:60-64.
24. Demarchi F., Bertoli C., Sandy P., et al. Glycogen synthase kinase-3beta regulates NF-kappa b1/p105 stability. J Biol Chem 2003, 278:39583-39590.
25. Steinbrecher K.A., Wilson W., Cogswell P.C., et al. Glycogen synthase kinase-3beta functions to specify gene specific, NF-kappaB-dependent transcription. Mol Cell Biol 2005, 25:8444-8455.
26. Kai J.I., Huang W.C., Tsai C.C., et al. Glycogen synthase kinase-3β indirectly facilitates interferon-γ-induced nuclear factor-κB activation and nitric oxide biosynthesis. J Cell Biochem 2010, 111:1522-1530.
27. Buss H., Dörrie A., Schmitz M.L., et al. Phosphorylation of serine 468 by GSK-3β negatively regulates basal p65 NF-κB activity. J Biol Chem 2004, 279:49571-49574.
28. Suganthi M., Sangeetha G., Benson C.S., et al. In vitro mechanisms involved in the regulation of cell survival by lithium chloride and IGF-1 in human hormone-dependent breast cancer cells (MCF-7). Toxicol Lett 2012, 214:182-191.
29. Azim K., Butt A.M. GSK-3β negatively regulates oligodendrocyte differentiation and myelination in vivo. Glia 2011, 59:540-553.
30. Gunn W.G., Krause U., Lee N., et al. Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood 2011, 117:1641-1651.
31. Bao H., Ge Y., Zhuang S., et al. Inhibition of glycogen synthase kinase-3β prevents NSAID-induced acute kidney injury. Kidney Int 2012, 81:662-673.
32. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
33. Boissier M.C. Cell and cytokine imbalances in rheumatoid synovitis. Joint Bone Spine 2011, 78:230-234.
34. Liu S., Yu S., Hasegawa Y., et al. Glycogen synthase kinase-3β is a negative regulator of growth factor induced activation of the c-Jun N-terminal kinase. J Biol Chem 2004, 279:51075-51081.
35. Takada Y., Fang X., Jamaluddin M.S., et al. Genetic deletion of glycogen synthase kinase-3β abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 2004, 279:39541-39554.
36. Guha M., Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002, 277:32124-32132.
37. Kim J.W., Lee J.E., Kim M.J., et al. Glycogen synthase kinase-3β is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem 2003, 278:13995-14001.
38. Wang M.J., Huang H.Y., Chen W.F., et al. Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades. J Neuroinflammation 2010, 7:99.
39. Thornton T.M., Pedraza-Alva G., Deng B., et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK-3beta inactivation. Science 2008, 320:667-670.
40. Cuzzocrea S., Mazzon E., Di Paola R., et al. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol 2006, 120:57-67.